By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



3925 West Braker Lane

Austin  Texas  78759  U.S.A.
Phone: 512-961-1891 Fax: 512-305-0009



Company News
Savara Announces FDA Grant of Qualified Infectious Disease Product (QIDP) And Fast Track Designation For Its Lead Product, AeroVanc 12/10/2013 11:25:05 AM
Savara Appoints Two New Members To Its Board of Directors 12/5/2013 6:27:07 AM
Cystic Fibrosis Foundation Therapeutics, Inc. Provides Savara $1.7 Million Award for Development of AeroVanc for MRSA Lung Infection in Cystic Fibrosis Patients 10/17/2013 10:47:30 AM
Savara Updates Series B Funding Tranche to $14.3 Million 6/26/2013 8:43:46 AM
Success With an Angel Syndicate: How One Pharma Startup, Savara, Raised $16 Million Without VCs 6/18/2013 7:40:31 AM
Savara Initiates Phase 2 Clinical Trial of AeroVanc for MRSA Lung Infection in Cystic Fibrosis Patients 4/18/2013 9:52:46 AM
Savara Lands $7.4 Million to Close a $16 Million Series B Round 3/21/2013 8:33:58 AM
Savara Announces Formation of Clinical Advisory Board 2/26/2013 9:40:37 AM
Savara' AeroVanc Granted U.S. Orphan Drug Designation for the Treatment of MRSA Lung Infection in Cystic Fibrosis Patients 11/13/2012 10:19:15 AM
Keiretsu Forum Members Make Substantial Bet on Savara 7/17/2012 10:44:25 AM